The aim of this study is to determine whether it is safe and effective to give the
Angiotensin Receptor Blocker (ARB) Candesartan within the first 72 hours following acute
stroke.
The aim of this study is to determine whether it is safe and effective to give the
Angiotensin Receptor Blocker (ARB) Candesartan within the first 72 hours following acute
stroke.
The purpose of this trial is to assess whether the blood pressure lowering agent candesartan
(an angiotensin receptor type 1 blocker) is effective when given to patients with acute
stroke and elevated blood pressure.
Hypothesis:
AT1 receptor blockade with candesartan in acute stroke will:
1. reduce the risk of death or major disability at 6 months by a 6% absolute risk
reduction, relative to placebo.
2. reduce the risk of the combined event of "vascular" death, myocardial infarction, or
stroke during the first 6 months by a 25% relative risk reduction, relative to placebo
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
